Finance

Beta
Lists
22UA:FRA
BioNTech SE - ADR
€82.10
+1.99%
(+1.60) 1D
May 29, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 22UA...
Open
€80.10
High
€83.00
Low
€80.05
Mkt. cap
24.26B
Avg. vol.
1.40K
Volume
6.01K
52-wk high
€111.60
52-wk low
€68.00
No. of employees
8K
Open
€80.10
High
€83.00
Low
€80.05
Mkt. cap
24.26B
Avg. vol.
1.40K
Volume
6.01K
52-wk high
€111.60
52-wk low
€68.00
No. of employees
8K
News stories
From sources across the web
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases. The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes. In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR
CEOUğur Şahin
Employees7.81K
Founded2008
Headquarters-
SectorBiotechnology
Websitebiontech.de
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
260.80M
1.52B
907.40M
118.10M
Cost of goods sold
76.40M
148.30M
302.80M
71.40M
Cost of revenue
76.40M
148.30M
302.80M
71.40M
Research and development expenses
509.10M
564.80M
505.40M
557.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
137.40M
148.50M
217.90M
150.80M
Operating expense
621.10M
1.40B
907.20M
727.70M
Total operating expenses
697.50M
1.55B
1.21B
799.10M
Operating income
-436.70M
-33.00M
-302.60M
-681.00M
Other non operating income
105.40M
96.80M
-173.80M
42.10M
EBT including unusual items
-402.70M
24.70M
-227.40M
-568.10M
EBT excluding unusual items
-379.30M
40.70M
-206.50M
-567.80M
Income tax expense
-16.10M
53.40M
77.60M
-36.20M
Effective tax rate
4.00%
216.19%
-34.12%
6.37%
Other operating expenses
-25.40M
690.30M
183.90M
19.90M
Net income
-386.60M
-28.70M
-305.00M
-531.90M
Net profit margin
-148.24%
-1.89%
-33.61%
-450.38%
Earnings per share
-1.60
-0.12
-0.33
-1.95
Interest and investment income
-
-
265.50M
61.70M
Interest expense
-6.60M
-2.60M
-
-4.00M
Net interest expenses
-6.60M
-2.60M
265.50M
57.70M
Depreciation and amortization charges
-
-
-
-
EBITDA
-385.70M
91.20M
-266.95M
-559.70M
Gain or loss from assets sale
-300.00K
-1.30M
-800.00K
-100.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer